LRMR Bathi resik saben saham sajrone 12 wulan pungkasan Larimar Therapeutics, Inc.

Larimar Therapeutics (LRMR) TTM net income per share demonstrates the impact of optimized distribution of neurological agents through partner laboratories, while the -1.99 mark reflects the latest data. However, high capital requirements and the risk of clinical trial failure for the Friedreich's ataxia drug create instability. The environmental profile is limited solely to compliance with chemical disposal regulations at research centers.

LRMR Bathi saben saham sajroning taun lumaku Larimar Therapeutics (04.07.2022 - 15.11.2026)

Larimar Corp - rincian analitis lan metrik utama (LRMR)

- rega saham lan target rega konsensus:

Rega saham Larimar Corp|LRMR - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Biji pasar Larimar Therapeutics Inc|LRMR - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Larimar Therapeutics|LRMR - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku larimartx.com|LRMR - Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Utang marang Ekuitas Larimar Therapeutics|LRMR - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Larimar Therapeutics Inc|LRMR - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Larimar Pharma|LRMR - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Larimar Therapeutics|Likuiditas cepet larimartx.com

- data bathi lan kelipatan valuasi:

LRMR - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Larimar Therapeutics|LRMR - Pangali P/E|Rega marang bathi mangsa ngarep Larimar Pharma|LRMR - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Larimar Therapeutics|LRMR - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Larimar Therapeutics|LRMR - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan larimartx.com|LRMR - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Larimar Therapeutics

- rincian pendapatan lan dodolan emiten:

LRMR - Pendapatan dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan Larimar Therapeutics, Inc.|LRMR - Rasio kapitalisasi pasar marang pendapatan|Multiplikator forward rega marang pendapatan Larimar Therapeutics, Inc.|LRMR - Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur

Analisis dhasar perusahaan:larimartx.com (LRMR)

The development of Friedreich's ataxia therapy via the drug Nomlabofusp defines the capital expenditure profile of Larimar Therapeutics (LRMR), where the rolling annual earnings per share visualize the efficiency of innovation monetization. This metric aggregates annual net income distributed per share, allowing investors to assess the real profitability of the business regardless of capital dilution and to recognize stagnation in fundamental value in a timely manner.

Analisis perusahaan pesaing